melatonin has been researched along with Tuberous Sclerosis in 4 studies
Tuberous Sclerosis: Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine normal melatonin excretion patterns in healthy children without sleep disorder and to compare these with those of patients with tuberous sclerosis complex and sleep disorder responsive to exogenous melatonin, we measured 6-sulfatoxymelatonin excretion in 21 healthy children and in 7 patients with tuberous sclerosis complex and sleep disorder responsive to melatonin (a 5 mg oral dose increasing total sleep time)." | 9.11 | Melatonin excretion in normal children and in tuberous sclerosis complex with sleep disorder responsive to melatonin. ( English, J; Hancock, E; O'Callaghan, F; Osborne, JP, 2005) |
| "We report a randomized, double-blind, controlled, crossover trial investigating the response to oral melatonin using two dose regimens in patients with sleep disorders associated with tuberous sclerosis complex." | 9.11 | Effect of melatonin dosage on sleep disorder in tuberous sclerosis complex. ( Hancock, E; O'Callaghan, F; Osborne, JP, 2005) |
| "The results of a therapeutic trial of the use of melatonin in patients with tuberous sclerosis complex who also have severe sleep problems are reported." | 9.09 | Use of melatonin to treat sleep disorders in tuberous sclerosis. ( Clarke, AA; Hancock, E; Hunt, A; O'Callaghan, FJ; Osborne, JP, 1999) |
| "To determine normal melatonin excretion patterns in healthy children without sleep disorder and to compare these with those of patients with tuberous sclerosis complex and sleep disorder responsive to exogenous melatonin, we measured 6-sulfatoxymelatonin excretion in 21 healthy children and in 7 patients with tuberous sclerosis complex and sleep disorder responsive to melatonin (a 5 mg oral dose increasing total sleep time)." | 5.11 | Melatonin excretion in normal children and in tuberous sclerosis complex with sleep disorder responsive to melatonin. ( English, J; Hancock, E; O'Callaghan, F; Osborne, JP, 2005) |
| "We report a randomized, double-blind, controlled, crossover trial investigating the response to oral melatonin using two dose regimens in patients with sleep disorders associated with tuberous sclerosis complex." | 5.11 | Effect of melatonin dosage on sleep disorder in tuberous sclerosis complex. ( Hancock, E; O'Callaghan, F; Osborne, JP, 2005) |
| "The results of a therapeutic trial of the use of melatonin in patients with tuberous sclerosis complex who also have severe sleep problems are reported." | 5.09 | Use of melatonin to treat sleep disorders in tuberous sclerosis. ( Clarke, AA; Hancock, E; Hunt, A; O'Callaghan, FJ; Osborne, JP, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braam, W | 1 |
| Smits, MG | 1 |
| Didden, R | 1 |
| Korzilius, H | 1 |
| Van Geijlswijk, IM | 1 |
| Curfs, LM | 1 |
| Hancock, E | 3 |
| O'Callaghan, F | 2 |
| English, J | 1 |
| Osborne, JP | 3 |
| O'Callaghan, FJ | 1 |
| Clarke, AA | 1 |
| Hunt, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Controlled-Release Melatonin (Melatonin CR)for the Treatment of Impaired Sleep Maintenance (ISM) in 4-8 Year Old Children With Autism Spectrum Disorders (ASD).[NCT01033565] | Phase 4 | 1 participants (Actual) | Interventional | 2010-03-04 | Terminated (stopped due to Unsuccessful in recruiting appropriate subjects.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assigns numerical score indicating level of improvement compared to baseline. Scale is rated from 1-7: 1= very much improved; 2= much improved; 3= minimally improved; 4= no change; 5= minimally worse; 6= much worse; 7= very much worse. (NCT01033565)
Timeframe: 2 weeks
| Intervention | units on a scale (Number) |
|---|---|
| Natrol | 2 |
1 review available for melatonin and Tuberous Sclerosis
| Article | Year |
|---|---|
Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis.
Topics: Angelman Syndrome; Central Nervous System Depressants; Child; Child Development Disorders, Pervasive | 2009 |
3 trials available for melatonin and Tuberous Sclerosis
| Article | Year |
|---|---|
Melatonin excretion in normal children and in tuberous sclerosis complex with sleep disorder responsive to melatonin.
Topics: Administration, Oral; Adolescent; Antioxidants; Case-Control Studies; Child; Child, Preschool; Circa | 2005 |
Effect of melatonin dosage on sleep disorder in tuberous sclerosis complex.
Topics: Administration, Oral; Adult; Antioxidants; Child; Child, Preschool; Cross-Over Studies; Dose-Respons | 2005 |
Use of melatonin to treat sleep disorders in tuberous sclerosis.
Topics: Adolescent; Adult; Child, Preschool; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 1999 |